Author(s): R.C. Pantola, Rakesh Bahuguna

Email(s): ,

DOI: Not Available

Address: R.C. Pantola*, Rakesh Bahuguna
Quality Control Department, Ind-Swift Laboratories Limited. Village Bhagwanpur, Barwala Road, Near Derabassi, Distt. S.A.S. Nagar (Mohali) Pin -140507 Punjab, India.
*Corresponding Author

Published In:   Volume - 5,      Issue - 10,     Year - 2012

Phase purity of active pharmaceutical ingredients (API) affects a range of physical, chemical and biological properties such as dissolution rate, stability and bioavailability. The pharmaceutical industry has frequently recourse the milling, shifting and drying which causes the impacts on phase of products. The different phases of products known as polymorphism and has become the challenge in pharmaceutical industry, in order to meet the specific polymorph of an individual product with respect to its quality specification. Pharmaceutical solids often exhibit polymorphism, which leads to different physiological properties; therefore, the understanding of manufacturing and control of polymorphic forms are essential aspects for product development and regulatory compliances in the pharmaceutical industry. X-ray powder diffraction (XRPD) is generally used for the characterization of polymorphism. XRPD method provides an advantage over other means of analysis in that it is usually non-destructive nature. XRPD investigations can also be carried out under in situ conditions and specimens exposed to non-ambient conditions such as low or high temperature and humidity.

Cite this article:
R.C. Pantola, Rakesh Bahuguna. Polymorphism: Quality rationalization, mitigation and authentication strategies with respect to regulatory compliances in pharmaceutical industry. Research J. Pharm. and Tech. 5(10): October 2012; Page 1264-1269.

R.C. Pantola, Rakesh Bahuguna. Polymorphism: Quality rationalization, mitigation and authentication strategies with respect to regulatory compliances in pharmaceutical industry. Research J. Pharm. and Tech. 5(10): October 2012; Page 1264-1269.   Available on:


1      Phoenix K and Andrews J. Adopting a Risk - Based Approach to 21 CFR Part 11 Assessments, Pharmaceutical Engineering.  2003:23-4.

2      Corradini P. X-ray studies of conformation: observation of different geometries of the same molecule. Chem. Ind. (Milan) 1973: 55: 122-129.

3      Haleblian JK and McCrone WC. Pharmaceutical applications of polymorphism. J. Pharm. Sci. 1969:58: 911-929.

4      Haleblian JK. Characterization of habits and crystalline modifications of solids and their pharmaceutical applications. J. Pharm. Sci. 1975: 64: 1269-1288.

5      Michael L. Pharmaceutical process scale-up. ISBN:0-8247-0625-0.2006

6      Wadke DA, Serajuddin ATM and Jacobson H. "Preformulation testing." In HA Lieberman, L Lachman, and JB Schwartz (eds.) Pharmaceutical Dosage Forms: Tablets (Vol. 1). Marcel Dekker, Inc., New York, 1989,

7      Guidance for industry ANDAs. Centre for drug research Evluation and Research (CDER) /guidance/index.htm.

8      Vippagunta SR, Brittain HG and Grant DJW. "Crystalline solids," Adv. Drug Del. Rev. 2001:48:3-26.

9      Brittain HG and  Fiese EF. Effect of pharmaceutical processing on drug polymorphs and solvates. In H. G. Brittain (ed.) Polymorphism in Pharmaceutical Solids. Marcel Dekker, Inc.1999 New York.

10    Sun C and Grant DJW. Influence of crystal structure on the tableting properties of sulfamerazine polymorphs. Pharm. Res.2001: 18: 274-280.

11    Genck WJ. The effects of mixing on scale-up _ how crystallization and precipitation React. Chem. Process.2000: 63: 47.

12    Beckmann W. Seeding the desired polymorph: background, possibilities, imitations, and case studies. Org. Proc. Res. Dev.2000: 4: 372-383.

13    Bernstein J. Polymorphism in Molecular Crystals. Oxford, UK: Clarendon Press 2002.

14    Morris KR, Griesser UJ, Eckhardt CJ and Stowell JG. Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes. Adv. Drug Delivery Rev. 2001:48: 91-114.

15    Aguiar AJ, Krc J, Kinkel AW and Samyn JC. Effect of polymorphism on the absorption of chloramphenicol from chloramphenicol palmitate. J Pharm Sci 1967: 56: 847– 853.

16    Brittain HG. Polymorphism in Pharmaceutical Solids, Marcel Dekker, New York, 1999.

17    Byrn SR, Pfeiffer RR, Stephenson G, Grant DJW and  Gleason WB. Solid-state pharmaceutical chemistry. Chem Mater 1994: 6: 1148–1158.

18    Byrn S, Pfeiffer R, Ganey M, Hoiberg C and  Poochikian G. Pharmaceutical solids: a strategic approach to regulatory considerations. Pharm Res 1995: 12: 945–954.

19    International Conference on Harmonization Q6A Guideline: Specifications for New Drug Substances and Products: Chemical Substances, October 1999.

20    Yu L X, Furness M S, Raw A, Woodland K P, Nashed N E, Ramos E, Miller S P F, Adams R C, Fang F, Patel R M, Holcombe F O Jr, Chiu Yand Hussain AS. Scientific considerations of pharmaceutical solid polymorphism in abbreviated new drug applications. Pharm Res 2003: 20: 531– 536.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

56th percentile
Powered by  Scopus

SCImago Journal & Country Rank

Recent Articles


Not Available